𝔖 Bobbio Scriptorium
✦   LIBER   ✦

PCN80 THE BENEFITS OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) VERSUS CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) IN SWEDEN: RESULTS FROM A COST-EFFECTIVENESS ANALYSIS

✍ Scribed by MJ Nuijten; C Holmberg; S Walzer

Book ID
118611924
Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
82 KB
Volume
12
Category
Article
ISSN
1098-3015

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

PCN14 AN INDIRECT COMPARISON OF THE EFFI
PCN14 AN INDIRECT COMPARISON OF THE EFFICACY OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) OR BEVACIZUMAB PLUS CARBOPLATIN AND PACLITAXEL (BCP) VERSUS CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)
✍ S Walzer; J de Castro CarpeΓ±o; A Vergnenegre; C Chouaid; D Heigener; HG Bischoff πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 80 KB
9164 An indirect comparison of the effic
9164 An indirect comparison of the efficacy of bevacizumab plus cisplatin and gemcitabine (BCG) or bevacizumab plus carboplatin and paclitaxel (BCP) versus pemetrexed plus cisplatin (PC) and cetuximab plus vinorelbine and cisplatin (CVC) in patients (pts) with advanced or recurrent non-small cell cancer (NSCLC)
✍ Walzer, S.; de Castro Carpeno, J.; Vergnenegre, A.V.; Chouaid, C.; Heigener, D.F πŸ“‚ Article πŸ“… 2009 πŸ› Elsevier Science 🌐 English βš– 48 KB